Table 4.
Standardized incidence ratios for hepatocellular carcinoma among U.S. transplant recipients
| Characteristic | Non-liver recipients | Liver recipients | ||
|---|---|---|---|---|
| HCC cases | SIR (95%CI) | HCC cases | SIR (95%CI) | |
| All subjects | 35 | 0.8 (0.5–1.0) | 38 | 3.4 (2.4–4.6) |
| Sex | ||||
| Male | 30 | 0.7 (0.5–1.1) | 33 | 3.6 (2.5–5.0) |
| Female | 5 | 0.8 (0.3–2.0) | 5 | 2.6 (0.9–6.2) |
| Age at transplant, years | ||||
| <40 | 4 | 1.8 (0.5–4.6) | 1 | 2.9 (0.1–16) |
| 40–59 | 19 | 0.7 (0.4–1.1) | 22 | 3.0 (1.8–4.5) |
| ≥ 60 | 12 | 0.8 (0.4–1.3) | 15 | 4.5 (2.5–7.4) |
| HCV antibody | ||||
| Negative | 19 | 0.6 (0.4–0.9) | 9 | 2.0 (0.9–3.9) |
| Positive | 6 | 3.4 (1.2–7.4) | 16 | 5.0 (2.9–8.2) |
| HBsAg | ||||
| Negative | 21 | 0.5 (0.3–0.8) | 26 | 2.9 (1.9–4.4) |
| Positive | 4 | 6.5 (1.8–16) | 7 | 7.4 (3.0–15) |
| Diabetes mellitus | ||||
| No | 13 | 0.6 (0.3–1.0) | 19 | 2.8 (1.7–4.3) |
| Yes | 12 | 1.1 (0.6–2.0) | 10 | 6.2 (3.0–11) |
Abbreviations: HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HCC, hepatocellular carcinoma, SIR standardized incidence ratio; CI, confidence interval
Standardized incidence ratio calculations exclude subjects of unknown race/ethnicity (2,537 non-liver recipients, including one HCC case; 409 liver recipients, zero HCC cases), because expected cancer rates were not available for these subjects.